NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis $3.74 -0.09 (-2.35%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Personalis Stock (NASDAQ:PSNL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Personalis alerts:Sign Up Key Stats Today's Range$3.71▼$3.8850-Day Range$3.00▼$6.0452-Week Range$1.14▼$7.20Volume97,016 shsAverage Volume968,127 shsMarket Capitalization$330.27 millionP/E RatioN/ADividend YieldN/APrice Target$7.80Consensus RatingBuy Company OverviewPersonalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Read More… Personalis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScorePSNL MarketRank™: Personalis scored higher than 79% of companies evaluated by MarketBeat, and ranked 154th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 3 research reports in the past 90 days.Read more about Personalis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.40) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Personalis' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.41% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 4.1.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.66 Percentage of Shares Shorted6.41% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 4.1.Change versus previous month News and Social Media3.3 / 5News Sentiment0.92 News SentimentPersonalis has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Personalis this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Personalis to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,104.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Personalis' insider trading history. Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address PSNL Stock News HeadlinesPersonalis to Announce First Quarter 2025 Financial ResultsApril 23 at 8:25 AM | finance.yahoo.comIs Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires?April 23 at 8:25 AM | msn.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 25, 2025 | Golden Portfolio (Ad)Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence DetectionApril 22 at 6:00 AM | businesswire.com6PSNL : What 5 Analyst Ratings Have To Say About PersonalisApril 10, 2025 | benzinga.comPersonalis initiated with a Buy at Craig-HallumMarch 18, 2025 | markets.businessinsider.comCraig-Hallum Initiates Coverage of Personalis (PSNL) with Buy RecommendationMarch 18, 2025 | msn.comBTIG Reaffirms Their Buy Rating on Personalis (PSNL)March 18, 2025 | markets.businessinsider.comSee More Headlines PSNL Stock Analysis - Frequently Asked Questions How have PSNL shares performed this year? Personalis' stock was trading at $5.78 on January 1st, 2025. Since then, PSNL stock has decreased by 35.3% and is now trading at $3.74. View the best growth stocks for 2025 here. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) announced its quarterly earnings data on Thursday, February, 27th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.09. The company had revenue of $16.80 million for the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative trailing twelve-month return on equity of 66.07% and a negative net margin of 104.52%. Read the conference call transcript. When did Personalis IPO? Personalis (PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Top institutional investors of Personalis include Sumitomo Mitsui Trust Group Inc. (0.77%). Insiders that own company stock include John Stephen West, Christopher M Hall, Aaron Tachibana, Richard Chen and Stephen Michael Moore. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Unity Software (U) and Vuzix (VUZI). Company Calendar Last Earnings2/27/2025Today4/25/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:PSNL CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$7.80 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+108.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,300,000.00 Net Margins-104.52% Pretax Margin-104.50% Return on Equity-66.07% Return on Assets-41.34% Debt Debt-to-Equity RatioN/A Current Ratio4.68 Quick Ratio4.44 Sales & Book Value Annual Sales$84.61 million Price / Sales3.91 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book1.42Miscellaneous Outstanding Shares88,308,000Free Float67,751,000Market Cap$331.16 million OptionableOptionable Beta1.89 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:PSNL) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.